ClinicalTrials.gg
CompletedNCT00094809Updated Oct 17, 2018Results posted

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

A Phase 2 interventional study of Placebo and Pegfilgrastim in Colon Cancer, Colorectal Cancer and Rectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 2, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Feb 2003, registered Oct 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Colonic Neoplasms by Amgen — none open to participants now, none under way, none of them phase 3. Colonic Neoplasms · Amgen.

Enrollment
5th of 15
252 · median 150
Started
2003
the only one that year
Phase 2
9 of 15
none open now
Registered
2nd of 15
by date

Among the 15 studies in Colonic Neoplasms by Amgen, this one is the 5th largest by enrollment, is the only one that started in 2003, is one of 9 in phase 2, and was the 2nd registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

None of the 15 studies in Colonic Neoplasms by Amgen is open now. The open studies under Colonic Neoplasms, anywhere →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Colonic Neoplasms by Amgen as a file.
02

Study summary

The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with locally advanced or metastatic colorectal cancer. This study is considered to be "investigational" because the time between receiving pegfilgrastim and the next cycle of chemotherapy is only 11 days.

03

Conditions studied

  • Colon Cancer
  • Colorectal Cancer
  • Rectal Cancer

Keywords

  • Neulasta®
  • pegfilgrastim
  • Advanced
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy with curative intent.
  • or cytologically documented locally advanced or metastatic colorectal cancer. The site of the primary lesion must be or has been confirmed endoscopically, radiologically, or surgically to be or has been in the large bowel.
  • Measurable or evaluable disease.
  • performance status 0, 1 or 2
  • ≥ 12 weeks
  • All of the following: (1) ≥ 4 weeks must have elapsed from the time of major surgery and subjects must have recovered from the effects (e.g., laparotomy); (2) ≥ 2 weeks must have elapsed from the time of minor surgery and subjects must have recovered from the operation (insertion of a vascular access device is not considered major or minor surgery); (3) ≥ 4 weeks must have elapsed from the time of major radiotherapy (e.g., chest or bone palliative radiation therapy).
  • Subjects may have received prior therapy and one prior chemotherapy regimen for metastatic disease providing 30 days has elapsed from last chemotherapy dose.
  • Subject must have recovered from prior chemotherapy complications and in the opinion of the investigator, the subjects current status does not place the subject at risk for entry into the trial.
  • Subjects with prior exposure to both oxaliplatin and irinotecan will not be eligible to participate in this study. However, if subject received prior therapy with oxaliplatin, they will be eligible to receive the FOLFIRI regimen. If subject received prior therapy with irinotecan, they will be eligible to receive the FOLFOX regimen.
  • Age ≥ 18 years
  • ≥ 1.5 x 109/L
  • count ≥100 x 109/L
  • ≥ 9.0 g/dL (subjects may be receive a red blood cell transfusion to achieve this requirement)
  • Creatinine ≤ 1.5 x UNL
  • Total ≤ 1.5 mg/dL (≤ 25.65 μmol/L), regardless of whether subjects have liver involvement secondary to tumor
  • ≤ 5 x UNL
  • Alkaline phosphatase ≤ 5 x UNL
  • to participate on the study.

Exclusion criteria

Exclusion Criteria:

  • Standard chemoradiation as treatment for colorectal cancer will be allowed, but prior radiotherapy to >15% of bone marrow or outside of standard adjuvant colorectal cancer chemoradiation is not allowed.
  • Known central nervous system or carcinomatous meningitis.
  • Predisposing colonic or small bowel disorders in which the symptoms are uncontrolled as indicated by baseline pattern of >3 loose stools daily in subjects without a colostomy or ileostomy. Subjects with a colostomy or ileostomy may be entered at the Investigator's discretion.
  • Pleural effusion or ascites, which cause respiratory compromise (≥Grade 2 dyspnea).
  • Concurrent use of other agents.
  • No active infection requiring the start of systemic (intravenous or oral) anti-infective (antibiotic, antifungal, antiviral) within 72 hours of the administration of the first cycle of study chemotherapy.
  • Symptomatic sensory peripheral neuropathy.
  • The following conditions: Uncontrolled high blood pressure; unstable angina; symptomatic congestive heart failure; myocardial infarction ≤ 6 months prior to randomization; serious uncontrolled cardiac arrhythmia; classification III or IV.
  • Prior , except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinomas, or other cancer from which the patient has been disease-free for at least five years.
  • Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.
  • Medical or psychiatric conditions which, in the opinion of the Investigator, make participation in an investigational trial of this nature a poor risk.
  • Known sensitivity to E. coli derived products (e.g., Filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A) or known sensitivity to any of the products to be administered during dosing.
  • Subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s).
  • Subject of is evidently pregnant (e.g., positive HCG test) or is breast feeding.
  • Subject is not using adequate precautions.
  • Subject will not be available for follow-up assessment.
  • Concerns for subject's compliance with the protocol procedures.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Active comparator
    Pegfilgrastim

    6 mg pegfilgrastim

    Drug: Pegfilgrastim

  • Placebo comparator
    Placebo

    6 mg placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.

  • Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Grade 3 or 4 Neutropenia

    Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) \< 1 x 10\^9/L, in any of the first four cycles of treatment

    Time frame: First 4 cycles of treatment (8 weeks)

  2. Grade 4 Neutropenia

    Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) \<0.5 x 10\^9/L, in any of the first four cycles of treatment

    Time frame: First 4 cycles of treatment (8 weeks)

Secondary outcomes

  1. Dose Delay or Reduction Due to Neutropenia

    Dose delay or reduction in chemotherapy doses due to neutropenia

    Time frame: First 4 cycles of treatment (8 weeks)

  2. Dose Delay or Reduction for Any Reason

    Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason

    Time frame: First 4 cycles of treatment (8 weeks)

  3. Febrile Neutropenia

    Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC \< 1.0 x 10\^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.

    Time frame: First 4 cycles of treatment (8 weeks)

  4. Hospitalization Due to a Neutropenia-Related Event

    Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment

    Time frame: First 4 cycles of neutropenia (8 weeks)

  5. Progression-Free Survival

    Kaplan-Meier estimate of the median time to disease progression or death

    Time frame: Up to 24 months after first four cycles of treatment

  6. Objective Tumor Response

    Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.

    Time frame: First 4 cycles of treatment (8 weeks)

  7. Survival

    Death from any cause through the end of the follow-up period

    Time frame: Up to 24 months after first four cycles of treatment

  8. Antibiotic Use Due to Febrile Neutropenia

    Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.

    Time frame: First 4 cycles of treatment (8 weeks)

07

Results

Posted Jan 6, 2011

Participant flow

Participants were enrolled from 12 February 2003 through 13 January 2006

Participant flow — Overall Study
MilestonePegfilgrastim (Neulasta)Placebo
Started126126
Received study drug124118
Properly consented; received study drug123118
Completed all 4 cycles of treatment9890
Completed7461
Not completed5265
Withdrew: Protocol deviation22
Withdrew: Noncompliance10
Withdrew: Adverse event31
Withdrew: Withdrawal by subject89
Withdrew: Disease progression33
Withdrew: Physician decision35
Withdrew: Lost to follow-up66
Withdrew: Death1925
Withdrew: Protocol-specified criteria11
Withdrew: Other24
Withdrew: Informed consent signed after treatment10
Withdrew: Study drug not received28
Withdrew: Other11

Outcome measures

PrimaryGrade 3 or 4 Neutropenia

Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) \< 1 x 10\^9/L, in any of the first four cycles of treatment

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Grade 3 or 4 Neutropenia
ParticipantsPegfilgrastim (Neulasta)Placebo
Grade 3 or 4 Neutropenia1651
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = <0.0001 · Odds ratio (or): 0.19 · 95% CI 0.10 to 0.37Common odds ratio of the pegfilgrastim group compared to the placebo group
SecondaryDose Delay or Reduction Due to Neutropenia

Dose delay or reduction in chemotherapy doses due to neutropenia

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Dose Delay or Reduction Due to Neutropenia
ParticipantsPegfilgrastim (Neulasta)Placebo
Dose Delay or Reduction Due to Neutropenia526
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = <0.0001 · Treatment difference: -18 · 95% CI -26.2 to -9.8Treatment difference in percentage of participants (pegfilgrastim group - placebo group)
SecondaryDose Delay or Reduction for Any Reason

Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Dose Delay or Reduction for Any Reason
ParticipantsPegfilgrastim (Neulasta)Placebo
Dose Delay or Reduction for Any Reason4153
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.0646 · Treatment difference: -12 · 95% CI -23.7 to 0.5Treatment difference in percentage of participants (pegfilgrastim group - placebo group)
SecondaryFebrile Neutropenia

Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC \< 1.0 x 10\^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Febrile Neutropenia
ParticipantsPegfilgrastim (Neulasta)Placebo
Febrile Neutropenia310
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.0384 · Odds ratio (or): 0.27 · 95% CI 0.07 to 1.00Common odds ratio of pegfilgrastim group compared to placebo group
SecondaryHospitalization Due to a Neutropenia-Related Event

Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment

Time frame:
First 4 cycles of neutropenia (8 weeks)
Reported as:
Number · Participants
Hospitalization Due to a Neutropenia-Related Event
ParticipantsPegfilgrastim (Neulasta)Placebo
Hospitalization Due to a Neutropenia-Related Event79
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.5514 · Odds ratio (or): 0.73 · 95% CI 0.26 to 2.04Common odds ratio for pegfilgrastim group compared to placebo group
SecondaryProgression-Free Survival

Kaplan-Meier estimate of the median time to disease progression or death

Time frame:
Up to 24 months after first four cycles of treatment
Reported as:
Median · Days
Progression-Free Survival
DaysPegfilgrastim (Neulasta)Placebo
Progression-Free Survival318 (258 to 387)322 (268 to 387)
SecondaryObjective Tumor Response

Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Objective Tumor Response
ParticipantsPegfilgrastim (Neulasta)Placebo
Objective Tumor Response3437
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.5434 · Treatment difference: -3.5 · 95% CI -14.8 to 7.8Treatment difference (pegfilgrastim group - placebo group) in the percentage of participants with a complete or partial response
SecondarySurvival

Death from any cause through the end of the follow-up period

Time frame:
Up to 24 months after first four cycles of treatment
Reported as:
Number · Participants
Survival
ParticipantsPegfilgrastim (Neulasta)Placebo
Survival4749
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Treatment difference: -12.1 · 95% CI -28.1 to 4.0Kaplan-Meier estimates of the difference in percent mortality for the pegfilgrastim group - placebo group. Median survival time was not reached for the pegfilgrastim group.
SecondaryAntibiotic Use Due to Febrile Neutropenia

Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Antibiotic Use Due to Febrile Neutropenia
ParticipantsPegfilgrastim (Neulasta)Placebo
Antibiotic Use Due to Febrile Neutropenia28
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.0457 · Odds ratio (or): 0.23 · 95% CI 0.05 to 1.09Common odds ratio for pegfilgrastim group compared to placebo group
PrimaryGrade 4 Neutropenia

Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) \<0.5 x 10\^9/L, in any of the first four cycles of treatment

Time frame:
First 4 cycles of treatment (8 weeks)
Reported as:
Number · Participants
Grade 4 Neutropenia
ParticipantsPegfilgrastim (Neulasta)Placebo
Grade 4 Neutropenia1317
Statistical analysis
  • Pegfilgrastim (Neulasta) vs Placebo · Mantel Haenszel · p = 0.3792 · Odds ratio (or): 0.71 · 95% CI 0.32 to 1.53Common odds ratio of the pegfilgrastim group compared to the placebo group

Adverse events

Collected over During treatment period and including 30 days after last dose of IP. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—36/117 (30.8%)108/117 (92.3%)
Pegfilgrastim—44/124 (35.5%)112/124 (90.3%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventPlaceboPegfilgrastim
DehydrationMetabolism and nutrition disorders6/11714/124
NauseaGastrointestinal disorders7/1172/124
NeutropeniaBlood and lymphatic system disorders2/1177/124
DiarrhoeaGastrointestinal disorders3/1177/124
Febrile neutropeniaBlood and lymphatic system disorders6/1173/124
VomitingGastrointestinal disorders6/1172/124
PneumoniaInfections and infestations2/1175/124
Abdominal painGastrointestinal disorders3/1171/124
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1172/124
Deep vein thrombosisVascular disorders3/1171/124
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlaceboPegfilgrastim
NauseaGastrointestinal disorders53/11769/124
DiarrhoeaGastrointestinal disorders53/11762/124
NeutropeniaBlood and lymphatic system disorders55/11711/124
FatigueGeneral disorders44/11749/124
AnaemiaBlood and lymphatic system disorders32/11736/124
VomitingGastrointestinal disorders22/11735/124
AnorexiaMetabolism and nutrition disorders14/11729/124
Abdominal painGastrointestinal disorders16/11722/124
AstheniaGeneral disorders6/11722/124
Weight decreasedInvestigations8/11719/124

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pegfilgrastim (Neulasta)PlaceboTotal
Mean62.4 ± 12.2662.9 ± 13.2162.7 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Pegfilgrastim (Neulasta)PlaceboTotal
Female453479
Male7884162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegfilgrastim (Neulasta)PlaceboTotal
White or Caucasian10384187
Black or African American121224
Hispanic or Latino31619
Asian336
Japanese101
Native Hawaiian or Other Pacific Islander033
Other101
Chemotherapy Regimen
Chemotherapy Regimen(Participants)Pegfilgrastim (Neulasta)PlaceboTotal
FOIL303060
FOLFOX6158119
FOLFIRI323062
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013. PubMed 20378503 ↗
  • Lyman GH, Reiner M, Morrow PK, Crawford J. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015 Jul;26(7):1452-8. doi: 10.1093/annonc/mdv174. Epub 2015 Apr 7. PubMed 25851633 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2003 to primary completion in May 2006, 39 months.

Results were first posted in Jan 2011, 4 years 7 months after primary completion.

Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2004
First posted
Oct 26, 2004
StartActual
Feb 1, 2003
Primary completionActual
May 19, 2006
CompletionActual
Jan 23, 2008
Results first posted
Jan 6, 2011
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00094809
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 26, 2004
Start date
Feb 1, 2003
Primary completion
May 19, 2006
Completion
Jan 23, 2008
Results posted
Jan 6, 2011
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion